CLL004: Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia

Sponsor

Shanghai Zhangjiang Biotechnology Limited Company (Industry)

Overall Status

Suspended

CT.gov ID

NCT01982175

Collaborator

(none)

120

Enrollment

Location

Arm

131

Duration (Months)

0.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a phase II, prospective, multicenter, open-label study to evaluate the efficacy and safety of Alemtuzumab in patients with relapse and refractory B-cell chronic lymphocytic leukemia.

Condition or Disease	Intervention/Treatment	Phase
B-cell Chronic Lymphocytic Leukemia	Biological: Alemtuzumab	Phase 2

Study Design

Study Type:

Interventional

Anticipated Enrollment :

120 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Multi-center, Open, Prospective, Phase II Study of Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection in Patients With Relapse and Refractory B-cell Chronic Lymphocytic Leukemia

Study Start Date :

Jul 1, 2011

Actual Primary Completion Date :

Feb 1, 2021

Anticipated Study Completion Date :

Jun 1, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Alemtuzumab Patients receive Alemtuzumab escalated from initial dose of 3mg/day then 10mg/day and up to 30mg/day by intravenous infusion(if tolerated). when stable dose of 30mg/day is tolerated, Alemtuzumab is administrated at 30mg by IV infusion 3 times per week for up to 12 weeks (including escalation and stable dose period). After completion of 12 weeks treatment, or discontinuation of treatment within 12 weeks due to disease progression, patients will be visited every 3 months up to 1 year from enrollment or to death, whichever occurs first.	Biological: Alemtuzumab Escalation Phase: Initial Doses of Alemtuzumab 3mg/day by intravenous(IV) infusion until tolerated, then Alemtuzumab 10mg/day IV infusion until tolerated, then Alemtuzumab 30mg IV infusion until tolerated. Escalation to 30mg/day should be accomplished in 3~7 days. Stable dose Phase: Once 30mg/day infusion of Alemtuzumab was tolerated, then continue 3 times per week. The total duration of Alemtuzumab therapy including escalation and stable dose phase is 12 weeks. More than 30mg daily or 90mg weekly dose is prohibited -------------------------------------------------------------------------------- Other Names: Recombinant Humanized Anti-CD52 Mab

Arm

Intervention/Treatment

Experimental: Alemtuzumab

Patients receive Alemtuzumab escalated from initial dose of 3mg/day then 10mg/day and up to 30mg/day by intravenous infusion(if tolerated). when stable dose of 30mg/day is tolerated, Alemtuzumab is administrated at 30mg by IV infusion 3 times per week for up to 12 weeks (including escalation and stable dose period). After completion of 12 weeks treatment, or discontinuation of treatment within 12 weeks due to disease progression, patients will be visited every 3 months up to 1 year from enrollment or to death, whichever occurs first.

Biological: Alemtuzumab

Escalation Phase: Initial Doses of Alemtuzumab 3mg/day by intravenous(IV) infusion until tolerated, then Alemtuzumab 10mg/day IV infusion until tolerated, then Alemtuzumab 30mg IV infusion until tolerated. Escalation to 30mg/day should be accomplished in 3~7 days. Stable dose Phase: Once 30mg/day infusion of Alemtuzumab was tolerated, then continue 3 times per week. The total duration of Alemtuzumab therapy including escalation and stable dose phase is 12 weeks. More than 30mg daily or 90mg weekly dose is prohibited --------------------------------------------------------------------------------

Other Names:

Recombinant Humanized Anti-CD52 Mab

Outcome Measures

Primary Outcome Measures

Objective Response Rate(ORR) [up to 1 year]
Objective Response Rate was defined as the proportion of patients who have CR, PR during the study as evaluated according to National Comprehensive Cancer Network(NCCN) guideline 2010 response criteria. Response categories include Complete Response(CR) and Partial Response(PR). ORR=CR+PR

Secondary Outcome Measures

Progression-Free Survival [up to 1 year]
Progression-Free Survival was defined as the time from randomization to disease progression (PD) or death due to any cause, whichever comes first.
Disease Control Rate(DCR) [up to 1 year]
Patients were evaluated according to National Comprehensive Cancer Network(NCCN) guideline 2010 response criteria. The best response observed during the study is summarized. Response categories include Complete Response(CR), Partial Response(PR) and Stable Disease(SD). DCR=CR+PR+SD
Duration of Response(DOR) [up to 1 year]
Duration of response was analyzed for patients who achieved a complete release(CR) or partial release(PR) and was defined as the time from the first date of documented response to the date of disease progression or death due to any cause.
Overall Survival [up to 1 year]
Overall Survival was defined as the duration from randomization to death due to any cause.
Summary of patients with Adverse Events(AEs) [up to 1 year]
Analysis of patients with adverse experiences according to CTCAE Version 4.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

An established diagnosis of B-cell chronic lymphocytic leukemia(B-CLL)
Meet criteria of relapsed or refractory CLL
Presence of one or more measurable lesions
ECOG Score 0-1
Life expectancy > 3 months
Female patients with childbearing potential must have a negative serum pregnancy test, male and female patients must agree to use an effective contraceptive method while on study treatment, and for a minimum 1 year following study therapy.

Exclusion Criteria:

Less than 2 weeks from prior anti-cancer therapy.
Allergic to the antibody or any component of the investigational product.
Other severe, concurrent diseases, including mental disorders, serious cardiac functional capacity (Class III or IV), uncontrolled diabetes.
Use of investigational agents rather than Alemtuzumab.
Active systematic infection or major organ malfunction requiring treatment.
Serum total bilirubin greater than or equal to 1.5 times upper limits of normal; or Serum alanine aminotransferase (ALT) and/or serum aspartate aminotransferase (AST) greater than or equal to 2.5 times upper limits of normal ( no liver metastases); or ALT and/or AST greater than or equal to 5 times upper limits of normal (liver metastases).
Blood urea nitrogen(BUN) greater than or equal to 1.5 times upper limits of normal or Serum creatinine greater than or equal to 1.5 times upper limits of normal.
White blood cell(WBC) count< 3.5×109/L or Absolute neutrophil count(ANC)<1.5×109/L or platelet count<75×109/L or Hemoglobin<80g/L.
Human immunodeficiency virus (HIV) positive.
Active hepatitis or a history of prior viral hepatitis B or C, or positive hepatitis B serologies without prior immunization.
Pregnant or nursing women.
Known central nervous system(CNS) metastases with B-CLL.
Active secondary malignancy.
cytomegalovirus(CMV) positive or immunodeficiency disease or after stem cell transplantation.